THE PRESENT INVENTION RELATES TO AN HLA-A*1101-RESTRICTED WT1 PEPTIDE, SPECIFICALLY, A PEPTIDE COMPRISING AN AMINO ACID SEQUENCE CONSISTING OF 9 CONTIGUOUS AMINO ACIDS FROM A WT1 PROTEIN, WHEREIN THE PEPTIDE HAS AN ABILITY TO BIND TO AN HLA-A*1101 MOLECULE, AND HAS AN ABILITY TO INDUCE A CTL. THE PRESENT INVENTION ALSO RELATES TO A PEPTIDE DIMER HAVING AN ABILITY TO BIND TO AN HLA-A*1101 MOLECULE AND HAVING AN ABILITY TO INDUCE A CTL, IN WHICH TWO PEPTIDE MONOMERS EACH COMPRISING AN AMINO ACID SEQUENCE CONSISTING OF CONTIGUOUS AMINO ACIDS FROM A WT1 PROTEIN AND COMPRISING AT LEAST ONE CYSTEINE RESIDUE ARE BOUND TO EACH OTHER THROUGH A DISULFIDE BOND. FURTHERMORE, THE PRESENT INVENTION RELATES TO A POLYNUCLEOTIDE ENCODING THE PEPTIDE, A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF A CANCER COMPRISING THE SAME AND THE LIKE.
